pentobarbital will lower the level or impact of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.

pentobarbital will minimize the extent or outcome of abemaciclib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration of abemaciclib with solid CYP3A4 inducers lessens plasma concentration of abemaciclib and its metabolites.

pentobarbital will lessen the level or impact of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will decrease the extent or result of alprazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will minimize the extent or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will decrease the extent or effect of darunavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.

With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.

pentobarbital will lessen the level or influence of maraviroc by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

pentobarbital will decrease the level or outcome of efavirenz by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unidentified.

Contraindicated (1)pentobarbital will decrease the extent or effect of elbasvir/grazoprevir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will decrease the extent or impact of cortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.

With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.

Contraindicated (one)pentobarbital will lower the extent or impact of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a delicate CYP3A4 substrate. Coadministration with powerful or reasonable website CYP3A4 inducers is contraindicated.

Contraindicated (one)pentobarbital decreases levels of vandetanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration with powerful CYP3A4 inducers; these drugs reduce exposure to vandetanib by nearly 40%.